“If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.
Studies in mice with Alzheimer’s disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects learning and memory, according to neurological researchers at the Rush University Medical Center.
Results from the National Institutes of Health funded study, recently were published in the Journal of Biological Chemistry.
“Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Alzheimer’s disease,” said Kalipada Pahan, PhD, the Floyd A. Davis professor of neurology at Rush and lead investigator of this study.
A family of proteins known as neurotrophic factors help in survival and function of neurons. Past research indicates that these proteins are drastically decreased in the brain of patients with Alzheimer’s disease (AD).
“Neurotrophic factor proteins could be increased in the brain by direct injection or gene delivery,” said Pahan. “However, using an oral medication to increase the level of these protein may be the best clinical option and a cost effective way to increase the level of these proteins directly in the brain.”
“Our study found that after oral feeding, Buphenyl enters into the brain, increases these beneficial proteins in the brain, protects neurons, and improves memory and learning in mice with AD-like pathology,” said Pahan.
In the brain of a patient with AD, two abnormal structures called plaques and tangles are prime suspects in damaging and killing nerve cells. While neurons die, other brain cells like astroglia do not die.
The study findings indicate that Buphenyl increases neurotrophic factors from astroglia. Buphenyl stimulates memory-related protein CREB (cyclic AMP response element-binding protein) using another protein known as Protein Kinase C (PKC) and increases neurotrophic factors in the brain.
“Now we need to translate this finding to the clinic and test Buphenyl in Alzheimer’s disease patients,” said Pahan. “If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
The Latest Bing News on:
Alzheimer’s
- Older Veterans with cognitive difficulties could mistakenly be diagnosed with Alzheimer's when PTSD is root causeon May 9, 2024 at 12:36 pm
A new study has investigated how measures of thinking, memory, and Alzheimer's disease risk group together in Veterans aged 65 and older without dementia. Results of the study showed multiple patterns of cognitive strengths and weaknesses and Alzheimer's ...
- ‘I’m a Neurologist, and This Is the Type of Nut I Swear by for Alzheimer’s Prevention'on May 9, 2024 at 3:25 am
While it’s impossible to prevent Alzheimer’s through diet alone (it’s a complicated disease with many factors at play), you can lower your risk by eating a diet rich in brain-healthy foods—and that includes snacks!
The Latest Google Headlines on:
Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Buphenyl
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSon May 2, 2024 at 7:34 pm
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSon May 2, 2024 at 1:01 pm
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through our ...
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSon May 1, 2024 at 5:00 pm
* The known adjustments are presented net of their related tax impact, which amount to approximately $2.61 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...
- Buphenyl Powderon February 14, 2012 at 12:42 pm
Sodium phenylbutyrate 940mg/gram; contains sodium 11.7g/100g of pwd. Adjunct in the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine ...
The Latest Google Headlines on:
Buphenyl
[google_news title=”” keyword=”Buphenyl” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]